Literature DB >> 19002758

Levosimendan and severe pulmonary hypertension during open heart surgery.

Ferit Cicekcioglu1, Ali Ihsan Parlar, Ozgur Ersoy, Kerem Yay, Alaa Hijazi, S Fehmi Katircioglu.   

Abstract

Weaning from cardiopulmonary bypass is the most important stage during mitral valve surgery, especially in patients with severe pulmonary hypertension. We report two patients with severe pulmonary hypertension who were operated on because of valvular heart disease. To reduce the pulmonary artery pressure, levosimendan was used because of its vasodilatory and cytoprotective effects. All patients tolerated the operation and levosimendan administration. Their postoperative course was uneventful. Levosimendan can be used to treat pulmonary hypertension during operations for heart valve disease. Patients clearly benefit from the vasodilator action of the drug for reducing pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002758     DOI: 10.1007/s11748-008-0301-4

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  10 in total

1.  Vasodilating mechanisms of levosimendan.

Authors:  Hisashi Yokoshiki; Nicholas Sperelakis
Journal:  Cardiovasc Drugs Ther       Date:  2003-03       Impact factor: 3.727

2.  Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

Authors:  H Yokoshiki; Y Katsube; M Sunagawa; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1997-08-27       Impact factor: 4.432

3.  Dear levosimendan, the right ventricle will thank you!

Authors:  Martin Westphal; Andrea Morelli; Hugo Van Aken
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

4.  Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.

Authors:  P Bowman; H Haikala; R J Paul
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

Review 5.  Mechanisms of action of calcium-sensitizing drugs.

Authors:  H Haikala; I B Linden
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

6.  An analysis of responses to levosimendan in the pulmonary vascular bed of the cat.

Authors:  Bracken J De Witt; Ikhlass N Ibrahim; Erin Bayer; Aaron M Fields; Todd A Richards; Ronald E Banister; Alan D Kaye
Journal:  Anesth Analg       Date:  2002-06       Impact factor: 5.108

Review 7.  Levosimendan, a new inotropic and vasodilator agent.

Authors:  Wolfgang G Toller; Christian Stranz
Journal:  Anesthesiology       Date:  2006-03       Impact factor: 7.892

8.  Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.

Authors:  Andrew D Michaels; Barry McKeown; Michael Kostal; Kalpesh T Vakharia; Mark V Jordan; Ivor L Gerber; Elyse Foster; Kanu Chatterjee
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

9.  Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery.

Authors:  János Pataricza; Irén Krassói; József Höhn; Attila Kun; Julius Gyula Papp
Journal:  Cardiovasc Drugs Ther       Date:  2003-03       Impact factor: 3.727

10.  Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension.

Authors:  J J Vincens; D Temizer; J R Post; L H Edmunds; H C Herrmann
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

  10 in total
  3 in total

1.  [Acute perioperative right heart insufficiency : Diagnostics and treatment].

Authors:  B Schäfer; C-A Greim
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

Review 2.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

3.  Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement.

Authors:  Tanveer Singh Kundra; P S Nagaraja; K S Bharathi; Parminder Kaur; N Manjunatha
Journal:  Ann Card Anaesth       Date:  2018 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.